肾细胞癌骨转移：免疫疗法对生存的影响
Bone Metastases in Renal Cell Carcinoma: Impact of Immunotherapy on Survival.
作者信息
Gambale Elisabetta, Palmieri Valeria Emma, Rossi Virginia, Francini Edoardo, Bonato Adele, Salfi Alessia, Galli Luca, Mela Marinella Micol, Pillozzi Serena, Antonuzzo Lorenzo
机构信息
Clinical Oncology Unit, Careggi University Hospital, Florence, Italy.
Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Prato, Italy.
出版信息
Cancer Diagn Progn. 2023 Sep 3;3(5):538-542. doi: 10.21873/cdp.10252. eCollection 2023 Sep-Oct.
BACKGROUND/AIM: We performed a multicenter retrospective observational study to investigate the impact of immune checkpoint inhibitors (ICIs) on the survival of patients with bone metastases (BMs) from renal cell cancer (RCC).
PATIENTS AND METHODS
A total of 98 patients with metastatic RCC (mRCC) treated with ICIs were retrospectively enrolled. All patients received standard treatments with nivolumab alone or in combination with ipilimumab from December 2015 to March 2022. The primary endpoint was median overall survival (OS).
RESULTS
Forty-three patients (44%) had radiological evidence of BMs. No statistically significant difference in OS was reported between the BM population and the entire population (p=0.254).
CONCLUSION
Our study suggests some degree of ICI activity to treat patients with BMs from RCC, historically associated with a poorer prognosis.
背景/目的：我们开展了一项多中心回顾性观察研究，以调查免疫检查点抑制剂（ICI）对肾细胞癌（RCC）骨转移（BM）患者生存的影响。
患者与方法
回顾性纳入了98例接受ICI治疗的转移性RCC（mRCC）患者。所有患者在2015年12月至2022年3月期间接受了纳武单抗单药或与伊匹木单抗联合的标准治疗。主要终点为中位总生存期（OS）。
结果
43例患者（44%）有BM的影像学证据。BM人群与总体人群的OS无统计学显著差异（p = 0.254）。
结论
我们的研究表明，ICI在治疗RCC骨转移患者方面有一定程度的活性，而RCC骨转移患者既往预后较差。
Zotero 插件